This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEA601E0_M.jpg
In this trial, IMVT-1402 demonstrated dose-dependent reductions in immunoglobulinG levels in healthy adults. Importantly, there were no dose-related changes observed in serum albumin or LDL-C.
These findings strengthen the case for IMVT-1402 as a potential leading candidate in the class of neonatal fragment crystallizable receptor (FcRn) inhibitors. Such inhibitors have the potential to play a significant role in the treatment of various medical conditions related to IgG and FcRn interactions.
“We are encouraged by the strong pharmacodynamic data observed to date with IMVT-1402,” said Pete Salzmann, M.D., chief executive officer of Roivant’s subsidiary Immunovant (NASDAQ:IMVT).
“These first-in-human results are consistent with those observed in prior non-human primate studies, and we look forward to sharing additional MAD data in November.”
Immunovant shares rose 7.5% on the news, while Roivant stock jumped 18.7%.
“While we want to see the full data presentation, this looks like a fairly definitive statement around safety–getting MAD PD/safety data at this update represents an upside surprise. When we see more granular results, we think safety/albumin impact is going to be of highest interest–from our read we think the wording around the MAD data in the PR are pretty clear,” Stifel analysts wrote in a flash note.
